Publications
NK Cells
G-Rex®10, G-Rex®100
Publication Date: May 14, 2016
A protocol for expanding human NK cells in G-Rex® gas-permeable flasks yields roughly 100-fold expansion within 8 to 10 days and supports retroviral CAR transduction. Peripheral blood mononuclear cells or apheresis products are co-cultured with irradiated K562mbIL15-41BBL feeder cells at a 10:1 feeder-to-NK ratio in CellGro SCGM with 10% serum and 500 U/mL IL-2. Each G-Rex®100 is seeded with 5 × 10^6 NK cells and 5 × 10^7 feeders in 400 mL, so 20 flasks give about 1 × 10^10 NK cells. Cultures typically need no feeding or cell manipulation during the 10-day expansion. After a 3-day transduction in retronectin-coated plates, CD19 and GD2 CAR constructs reached approximately 65–95% efficienc…
Publications
NK Cells
Publication Date: March 22, 2016
Ex vivo-expanded human NK cells can be genetically reprogrammed with a cGMP-compliant mRNA electroporation platform that gives rapid transgene expression in nearly all cells without harming viability or cytotoxicity. Electroporation with eGFP mRNA produced expression in nearly 100% of cells, with more than 95% positive for the first 7 to 9 days. Cells loaded with CCR7 mRNA, at 4 µg per million cells, showed dose-dependent migration toward the lymph node chemokine CCL19, whereas non-electroporated cells did not. Introducing mRNA for high-affinity CD16-158V into cells from CD16-158F/F donors raised CD16 expression and increased rituximab-dependent degranulation and killing of CD20-positive…
Publications
CAR T Cells
G-Rex®10
Publication Date: March 16, 2016
T cells carrying a ligand-based chimeric antigen receptor that uses full-length GM-CSF to target the GM-CSF receptor (CD116) suppressed the growth of juvenile myelomonocytic leukemia (JMML) CD34+ cells while sparing normal CD34+ cells. The piggyBac-engineered T cells were produced from healthy donors and two JMML patients; after 21 days of culture, three healthy donors yielded 5.2 ± 2.8 × 10^8 cells, with 40.9 ± 7.8 % of CD3+ cells expressing the receptor. In 2-day co-cultures at effector to target ratios of 1:1 and 1:4, CAR T cells markedly reduced JMML colony formation, whereas mock T cells left colonies at 102.7 and 99.3 % of control; cord blood and bone marrow CD34+ colonies were unaf…
Publications
CAR T Cells
Publication Date: November 4, 2015
The Go-CART is an in vitro six-chambered culture system that tracks CAR T cell migration, anti-tumor activity and persistence over more than two weeks without animals. Chambers C1 to C6 are joined by 2 mm channels forming an 11.5 cm S-shaped path, and the gas-permeable base avoids medium replenishment. After 72 hours, 24 μg of MCP1 placed in C1 produced a gradient from 196.79 ng/mL in C1 to 0.64 ng/mL in C6. With CAPAN1 tumor cells in an AlgiMatrix 3D model in C1 and 2.00E+07 CAR-PSCA T cells added to C6, T cells accumulated at the tumor site by day 5. Tumor signal fell from 3.52E+08 to 3.31E+07 p/s/cm2/sr by day 15, whereas without T cells it rose from 2.69E+08 to 2.47E+09.
Publications
Other
G-Rex®10, G-Rex®100
Publication Date: November 1, 2015
Lonza's Cells on Demand fresh human pancreatic islets are supplied as non-proliferating suspension aggregates shipped in primary passage in Wilson Wolf G-Rex® gas-permeable vessels, and they stay optimally viable at 22°C for about seven days from isolation. Each shipment must have at least 70% viability and 70% purity at shipping, with one islet equivalent defined as a 150 μm islet containing roughly 1,500-2,000 cells. Users equilibrate the vessel for three to four hours, replace about 50% of the medium every three to four days, count islets with dithizone staining, and assess function by glucose-stimulated insulin response after 12-24 hours at 37°C. The islets cannot be subcultured or cr…
Publications
T-Cells, VST Cells
Publication Date: September 21, 2015
A bispecific T-cell engager built from the TCR-mimic antibody ESK1 can direct T cells against the intracellular oncoprotein WT1 presented on HLA-A*02:01, even though few peptide-HLA complexes sit on the cell surface. ESK1-BiTE triggered dose-dependent T-cell activation and killing of WT1-positive SET-2 AML and BV173 ALL cells in chromium-release assays, with activity down to 1 ng/ml at a 1:1 effector-to-target ratio. In NSG mice with EBV-specific T cells, it suppressed SET-2 leukemia, primary ALL and JMN mesothelioma, and about threefold more T cells accumulated in liver, spleen and bone marrow. In cells from ovarian cancer patients, it also induced a secondary CD8 T-cell response to HER2…
Publications
TCR T Cells
G-Rex®100
Publication Date: August 21, 2015
Effector CD8+ T cells transferred into lymphodepleted mice depend on host IL-7, not IL-15, for initial engraftment, and this depends on elevated IL-7Rα expression on the donor cells. In irradiated mice, pmel-1 T cells activated with IL-12 (Tc1) expanded strongly, and IL-7 neutralization reduced their numbers at day 7 while IL-15 knockout did not. Tc1 cells from IL-7Rα heterozygous mice, with about half the receptor level, gave about half as many spleen donor cells and weaker antitumor activity against B16 melanoma. Strong TCR stimulation raised IL-7Rα without IL-12, and IL-12 during activation of human CD8+ T cells, including TCR-transduced cells, enhanced IL-7Rα expression after recultur…
Publications
Other
Publication Date: June 25, 2015
Exosomes released by acute myeloid leukemia cells help suppress residual blood-forming function in the bone marrow. In mice xenografted with Molm-14 or HL-60 cells, and after direct femoral injection of purified exosomes, colony formation by marrow progenitors fell, while Scf and Cxcl12 expression dropped in stromal cells. In vitro, Molm-14 exosomes reduced progenitor frequency by 36%, lowered CXCR4 and impaired migration toward CXCL12. Low-oxygen culture increased exosome release 2–3-fold. Proteomics of exosome-exposed progenitors found 282 differentially expressed proteins, including reduced DNMT1, HELLS and PCNA. HL-60 mice showed this effect without leukemia cells in the marrow.
Publications
TIL Cells
G-Rex®100M
Publication Date: June 5, 2015
Growing melanoma tumor-infiltrating lymphocytes (TIL) in a gas-permeable G-Rex® flask during the 14-day rapid expansion rescued lines that grew poorly in the standard flask-and-bag process. Across 10 TIL lines, median fold expansion was 2,653 in G-Rex® versus 1,210 with flask and bag (p = 0.08), and in four poorly growing lines the gain was significant (p = 0.007). TCR Vα and Vβ diversity was preserved, with no chain lost. On day 7, TIL from G-Rex® showed higher mitochondrial respiration, and OCR almost tripled after FCCP. Sorted CD8+BTLA+ TIL showed a more oxidative profile than BTLA− cells, with higher mitochondrial content.
Publications
CTL Cells
G-Rex®10
Publication Date: April 19, 2015
A clinic-ready protocol for generating HA-1-specific minor histocompatibility antigen T-cell lines showed that culture duration shapes exhaustion differently at each stage. Starting from 15 million PBMCs primed with peptide-loaded dendritic cells in a gas-permeable G-Rex®10 vessel, cultures expanded about 25 to 140-fold over four weeks. Antigen-specific CD8 cells were detectable by day 21, but a fourth stimulation at day 28 raised PD-1 and KLRG-1 on them. After IFNγ capture at day 21, a rapid expansion protocol gave roughly 2000-fold growth by day 21, without PD-1 or KLRG-1 induction, yet proliferation (Ki67) and the antigen-specific fraction declined. The authors propose no more than thr…
Publications
CAR T Cells, TCR T Cells, TIL Cells, VST Cells
Publication Date: February 27, 2015
Clinical-grade tumor-infiltrating lymphocytes, gene-engineered CAR or TCR T cells and virus-specific T cells can each be manufactured at scale under cGMP, but the processes differ greatly in length and complexity. This review describes standard TIL manufacture, which takes about 6–8 weeks, including a 2-week rapid expansion with irradiated feeder cells, anti-CD3 antibody and 6000 U/mL IL-2. A semi-closed CAR-T platform using Dynabeads, retroviral transduction and a WAVE bioreactor takes about 2 weeks. A CD8 central memory lentiviral platform yields over 1 billion cells within 35 days. Penta-viral-specific T cells grown in G-Rex® bioreactors reach therapeutic doses in about 10 days, versus…
Publications
CAR T Cells, VST Cells
G-Rex®100
Publication Date: February 18, 2015
Transducing multivirus-specific T cells (EBV, CMV, adenovirus) with a GD2-directed CAR on day 3 of culture, after only one stimulation, gave higher and more stable transgene expression than the previous day-19 approach. Early transduction reached a mean of 55% CAR-positive cells, versus 22% for late transduction, and the product held a higher share of central memory cells in 5 of 6 donors, with greater proliferation and higher TH1 cytokine output. Centrifuging retroviral supernatant onto retronectin-coated plates increased efficiency, and IL-4 and IL-7 improved expansion. In GMP validation runs, triVSTs expanded 5.4-fold after the first stimulation and 178-fold after the second, transgene…
No manuscripts match your filters.